These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. Kong D; Heath E; Chen W; Cher M; Powell I; Heilbrun L; Li Y; Ali S; Sethi S; Hassan O; Hwang C; Gupta N; Chitale D; Sakr WA; Menon M; Sarkar FH Am J Transl Res; 2012; 4(1):14-23. PubMed ID: 22347519 [TBL] [Abstract][Full Text] [Related]
25. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer. Wang D; Ding L; Wang L; Zhao Y; Sun Z; Karnes RJ; Zhang J; Huang H Oncotarget; 2015 Dec; 6(38):41045-55. PubMed ID: 26516927 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer. Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587 [TBL] [Abstract][Full Text] [Related]
27. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals. Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473 [TBL] [Abstract][Full Text] [Related]
28. Erratum: Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. Kong D; Heath E; Chen W; Cher M; Powell I; Heilbrun L; Li Y; Ali S; Sethi S; Hassan O; Hwang C; Gupta N; Chitale D; Sakr W; Menon M; Sarkar F Am J Transl Res; 2013; 6(1):102-103. PubMed ID: 24349627 [TBL] [Abstract][Full Text] [Related]
29. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822 [TBL] [Abstract][Full Text] [Related]
30. Let-7a inhibits proliferation and induces apoptosis by targeting EZH2 in nasopharyngeal carcinoma cells. Cai K; Wan Y; Sun G; Shi L; Bao X; Wang Z Oncol Rep; 2012 Dec; 28(6):2101-6. PubMed ID: 22972404 [TBL] [Abstract][Full Text] [Related]
31. Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells. Dimri M; Bommi PV; Sahasrabuddhe AA; Khandekar JD; Dimri GP Carcinogenesis; 2010 Mar; 31(3):489-95. PubMed ID: 19969553 [TBL] [Abstract][Full Text] [Related]
32. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271 [TBL] [Abstract][Full Text] [Related]
33. The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease. Kurul NO; Ates F; Yilmaz I; Narli G; Yesildal C; Senkul T Prostate; 2019 Jul; 79(10):1125-1132. PubMed ID: 31045265 [TBL] [Abstract][Full Text] [Related]
34. MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2. Pan MZ; Song YL; Gao F Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8795-8805. PubMed ID: 31696466 [TBL] [Abstract][Full Text] [Related]
35. The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells. Bryant RJ; Winder SJ; Cross SS; Hamdy FC; Cunliffe VT Prostate; 2008 Feb; 68(3):255-63. PubMed ID: 18095286 [TBL] [Abstract][Full Text] [Related]
36. [EZH2 expression in human prostate cancer and its clinicopathologic significance]. Li J; Fan QH; Fan XS; Zhou W; Qiu Y; Qiu L Zhonghua Nan Ke Xue; 2010 Feb; 16(2):123-8. PubMed ID: 20369694 [TBL] [Abstract][Full Text] [Related]
37. The long non-coding RNA PCSEAT exhibits an oncogenic property in prostate cancer and functions as a competing endogenous RNA that associates with EZH2. Yang X; Wang L; Li R; Zhao Y; Gu Y; Liu S; Cheng T; Huang K; Yuan Y; Song D; Gao S Biochem Biophys Res Commun; 2018 Jul; 502(2):262-268. PubMed ID: 29803673 [TBL] [Abstract][Full Text] [Related]
38. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer. Bohrer LR; Chen S; Hallstrom TC; Huang H Endocrinology; 2010 Nov; 151(11):5136-45. PubMed ID: 20881251 [TBL] [Abstract][Full Text] [Related]
39. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893 [TBL] [Abstract][Full Text] [Related]
40. Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer. Liu Q; Wang G; Li Q; Jiang W; Kim JS; Wang R; Zhu S; Wang X; Yan L; Yi Y; Zhang L; Meng Q; Li C; Zhao D; Qiao Y; Li Y; Gursel DB; Chinnaiyan AM; Chen K; Cao Q Int J Cancer; 2019 Jul; 145(2):415-426. PubMed ID: 30628724 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]